详情页 - 聚合机构库演示平台

资源类型：

文章类型：

作者：

Ying, Zhitao[1,2,3,4,5,6,7,8,9,10,11,12] * ; Song, Yuqin[1,2,3,4,5,6,7,8,9,10,11,12]

; Yang, Haiyan[1,2,3,4,5,6,7,8,9,10,11,12] ; Guo, Ye[1,2,3,4,5,6,7,8,9,10,11,12] ; Li, Wenyu[1,2,3,4,5,6,7,8,9,10,11,12] ; Zou, Dehui[1,2,3,4,5,6,7,8,9,10,11,12] ; Zhou, Daobin[1,2,3,4,5,6,7,8,9,10,11,12] ; Wang, Zhao[1,2,3,4,5,6,7,8,9,10,11,12]

; Zhang, Mingzhi[1,2,3,4,5,6,7,8,9,10,11,12] ; Wu, Jianqiu[1,2,3,4,5,6,7,8,9,10,11,12] ; Liu, Hui[1,2,3,4,5,6,7,8,9,10,11,12]

; Wang, Chris[1,2,3,4,5,6,7,8,9,10,11,12] ; Yang, Su[1,2,3,4,5,6,7,8,9,10,11,12] ; Zhou, Zisong[1,2,3,4,5,6,7,8,9,10,11,12] ; Qin, Yun[1,2,3,4,5,6,7,8,9,10,11,12] ; Zhu, Jun[1,2,3,4,5,6,7,8,9,10,11,12] ;

单位： [1]Peking Univ Canc & Hosp Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [2]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Peoples R China [4]Tongji Univ, Shanghai East Hosp, Oncol, Sch Med, Shanghai, Peoples R China [5]Guangdong Acad Sci, Guangdong Prov Peoples Hosp, Dept Lymphoma, Guangzhou, Peoples R China [6]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Dept Lymphoma & Myeloma, State Key Lab Expt Hematol, Tianjin, Peoples R China [7]Chinese Acad Med Sci, Dept Hematopathol, Peking Union Med Coll Hosp, Beijing, Peoples R China [8]Capital Med Univ, Beijing Friendship Hosp, Dept Hematopathol, Beijing, Peoples R China [9]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [10]Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China [11]Beijing Hosp, Dept Hematol, Beijing, Peoples R China [12]JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China

出处：

ISSN：

语种：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者单位： [1]Peking Univ Canc & Hosp Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [2]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Peoples R China [4]Tongji Univ, Shanghai East Hosp, Oncol, Sch Med, Shanghai, Peoples R China [5]Guangdong Acad Sci, Guangdong Prov Peoples Hosp, Dept Lymphoma, Guangzhou, Peoples R China [6]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Dept Lymphoma & Myeloma, State Key Lab Expt Hematol, Tianjin, Peoples R China [7]Chinese Acad Med Sci, Dept Hematopathol, Peking Union Med Coll Hosp, Beijing, Peoples R China [8]Capital Med Univ, Beijing Friendship Hosp, Dept Hematopathol, Beijing, Peoples R China [9]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [10]Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China [11]Beijing Hosp, Dept Hematol, Beijing, Peoples R China [12]JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma

文献详情